Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: Five-year results for the SENTRY Antimicrobial Surveillance Program

Diagnostic Microbiology and Infectious Disease

Volumn 46, Issue 4, 2003, Pages 285-289

  Gordon, Kelley A ^a   Biedenbach, Douglas J ^a   Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAMASE; CEFEPIME; CEFTRIAXONE; CIPROFLOXACIN; CLAVULANIC ACID; DALFOPRISTIN; LEVOFLOXACIN; QUINUPRISTIN; SULFAMETHOXAZOLE; TETRACYCLINE; TRIMETHOPRIM; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; HAEMOPHILUS INFLUENZAE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; NORTH AMERICA; PATHOGENESIS; PNEUMONIA; POPULATION RESEARCH; PREVALENCE; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE;

EID: 0042927965     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(03)00087-7     Document Type: Article

References (25)

1. Andrews J., Honeybourne D., Jevons G., Boyce M., Wise R., Bello A., Gajjar D. Concentrations of garenoxacin in plasma, bronchial mucosa, alveolar macrophages and epithelial lining fluid following a single oral 600 mg dose in healthy adult subjects. J Antimicrob Chemother. 51:2003;727-730.
2. Anonymous. Guidelines for prevention of nosocomial pneumoniae. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep. 46:1997;6-7.
3. Ballow C.H., Jones R.N., Johnson D.M., Deinhart J.A., Schentag J.J. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. Diagn Microbiol Infect Dis. 29:1997;173-186.
4. Barry A.L., Fuchs P.C., Brown S.D. Identification of β-lactamase-negative, ampicillin-resistant strains of Haemophilus influenzae with four methods and eight media. Antimicrob Agents Chemother. 45:2001;1585-1588.
5. Bartlett J.G., Mundy L.M. Community-acquired pneumonia. New Engl J Med. 333:1995;1618-1624.
6. Biedenbach D.J., Jones R.N. Fluoroquinolone-resistant Haemophilus influenzae Frequency of occurrence and analysis of confirmed strains in the SENTRY Antimicrobial Surveillance Program (North and Latin America) . Diagn Microbiol Infect Dis. 36:2000;255-259.
7. Biedenbach, D. J., & Jones, R. N. (2003). Five year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones: Prevalence results from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis (in press).
8. Chen D.K., McGeer A., de Azavedo J.C., Low D.E. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. New Engl J Med. 341:1999;233-239.
9. Doern G.V., Brueggemann A.B., Pierce G., Preston Holley H. Jr, Rauch A. Antibiotic resistance in the United States in 1994 and 1995 and detection of β-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study. Antimicrob Agents Chemother. 41:1997;292-297.
10. Doern G.V., Pfaller M.A., Kugler K., Freeman J., Jones R.N. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY Antimicrobial Surveillance Program. Clin Infect Dis. 27:1998;764-770.
11. Fung-Tomc J., Minassian C., Kolek B. Antibacterial spectrum of a novel des-fluoro(6)quinolone, BMS-284756. Antimicrob Agents Chemother. 44:2002;3351-3356.
12. Jernigan D.B., Cetran M.S., Breiman R.F. Minimizing the impact of drug resistant Streptococcus pneumoniae (DRSP) a strategy from the DRSP working group . J Am Med Assoc. 275:1996;206-209.
13. Jones R.N. Can antimicrobial activity be sustained? An appraisal of orally administered drugs used for respiratory tract infections. Diagn Microbiol Infect Dis. 27:1997;21-28.
14. Jones R.N., Pfaller M.A. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance Data from the SENTRY Antimicrobial Surveillance Program . Clin Infect Dis. 31:(Suppl 2):2000;S16-S23.
15. Jorgensen J.H., Doern G.V., Maher L.A., Howell A.W., Redding J.S. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother. 34:1990;2075-2080.
16. Khan W., Ross S., Rodriguez W., Controni G., Saz A.K. Haemophilus influenzae type b resistant to ampicillin a report of two cases . J Amer Med Assoc. 229:1974;298-301.
17. Lewis M.T., Gales A.C., Sader H.S., Pfaller M.A., Jones R.N. Frequency of occurrence and antimicrobial susceptibility patterns for pathogens isolated from Latin American patients with a diagnosis of pneumonia: results from the SENTRY antimicrobial surveillance program (1998). Diagn Microbiol Infect Dis. 37:2000;63-74.
18. Marco F., Garcia-de-Lomas J., Garcia-Rey C., Bouza E., Aguilar L., Fernandez-mazarrasa C. Antimicrobial susceptibilities of 1,730 Haemophilus influenzae respiratory tract isolates in Spain in 1998-1999. Antimicrob Agents Chemother. 45:2001;3226-3228.
19. Marston B.J., Plouffe J.F., File T.M. Jr, Hackman B.A., Salstrom S.J., Lipman H.B., Kolczak M.S., Breiman R.F. Incidence of community acquired pneumoniae requiring hospitalization. Results of a population based active surveillance study in Ohio. Arch Intern Med. 157:1997;1709-1718.
20. Mendelman P.M., Chaffin D.O., Stull T.L., Rubens C.E., Mack K.D., Smith A.L. Characterization of non-β-lactamase-mediated ampicillin resistance in Haemophilus influenzae. Antimicrob Agents Chemother. 26:1984;235-244.
21. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically Approved standard M7-A6 . 2003;NCCLS, Wayne, PA.
22. Performance standard for antimicrobial susceptibility testing. Document M100-S13. 2003;NCCLS, Wayne, PA.
23. Sader H.S., Gales A.C., Granacher T.D., Pfaller M.A., Jones R.N. Prevalence of Antimicrobial resistance among respiratory tract isolates in Latin America: results from the SENTRY Antimicrobial Surveillance Program (1997-98). Braz J Infect Dis. 4:2000;245-254.
24. Spencer R.C. Predominant pathogens found in the European prevalence of infection in intensive care study. Eur J Clin Microbiol Infect Dis. 15:1996;281-284.
25. Vincent J.L., Bihari D.J., Suter P.M., Bruining H.A., White J. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European prevalence of infection in intensive care (EPIC) study. EPIC International Advisory Committee. J Amer Med Assoc. 274:1995;639-645.